CONMED Corporation (CNMD) Income Statement
CNMD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCNMD revenue and net income
Where CNMD's revenue goes
2025Each bar shows an amount and its share of revenue. CNMD kept 3.4% of revenue as net income.
CNMD profit margins
CNMD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +5.2% | +9.5% | +9.8% | +6.7% |
| Gross profit | −1.0% | +8.3% | +9.5% | +6.6% |
| Operating income | −29.5% | +26.3% | +25.1% | +10.7% |
| Net income | −64.5% | — | +37.7% | +4.4% |
| EPS (diluted) | +10.8% | +20.3% | +16.4% | +10.6% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CNMD quarterly EPS vs estimates
CONMED beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: October 28, 2026 (estimate $1.00).
CNMD income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.37B | $1.31B | $1.24B | $1.05B | $1.01B | $862.5M | $955.1M | $859.6M | $796.4M | $763.5M |
| Cost of revenue | $649.1M | $574.0M | $568.5M | $474.2M | $442.6M | $402.2M | $430.4M | $390.5M | $365.4M | $355.2M |
| Gross profit | $725.4M | $733.0M | $676.2M | $571.2M | $568.0M | $460.3M | $524.7M | $469.1M | $431.0M | $408.3M |
| Research & development | $55.9M | $54.4M | $52.6M | $47.2M | $43.6M | $40.5M | $45.5M | $42.2M | $32.3M | $32.3M |
| Sales, general & admin | $592.0M | $454.0M | $505.8M | $454.0M | $414.8M | $373.8M | $400.1M | $355.6M | $351.8M | $338.4M |
| Total operating expenses | $584.2M | $532.7M | $555.6M | $501.2M | $458.3M | $414.3M | $445.6M | $397.8M | $384.1M | $370.7M |
| Operating income | $141.1M | $200.3M | $120.6M | $70.1M | $109.7M | $46.0M | $79.1M | $71.3M | $46.9M | $37.7M |
| Interest income | — | — | — | — | — | — | $42.7M | $20.7M | $18.2M | $15.4M |
| Interest expense | $31.1M | $37.3M | $39.8M | $28.9M | $35.5M | $44.1M | $42.7M | $20.7M | $18.2M | $15.4M |
| Income before taxes | $71.1M | $163.0M | $80.8M | −$70.9M | $73.1M | $1.6M | $31.2M | $50.7M | $28.7M | $19.4M |
| Income taxes | $24.1M | $30.6M | $16.4M | $9.7M | $10.6M | −$7.9M | $2.6M | $9.8M | −$26.8M | $4.7M |
| Net income | $47.1M | $132.4M | $64.5M | −$80.6M | $62.5M | $9.5M | $28.6M | $40.9M | $55.5M | $14.7M |
| EBITDA | $176.5M | $251.6M | $172.0M | $27.6M | $179.3M | $118.3M | $146.2M | $133.1M | $105.5M | $90.0M |
| EPS (diluted) | $4.61 | $4.16 | $3.45 | $2.65 | $3.21 | $2.16 | $2.65 | $2.18 | $1.90 | $1.61 |
| Gross margin | 52.8% | 56.1% | 54.3% | 54.6% | 56.2% | 53.4% | 54.9% | 54.6% | 54.1% | 53.5% |
| Operating margin | 10.3% | 15.3% | 9.7% | 6.7% | 10.9% | 5.3% | 8.3% | 8.3% | 5.9% | 4.9% |
| Net margin | 3.4% | 10.1% | 5.2% | −7.7% | 6.2% | 1.1% | 3.0% | 4.8% | 7.0% | 1.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $343.5M | $317.0M | $373.5M | $338.6M | $343.0M | $319.4M | $345.9M | $316.7M | $332.1M | $312.3M | $327.0M | $304.6M |
| Cost of revenue | $146.0M | $133.6M | $160.1M | $180.6M | $162.5M | $151.5M | $147.6M | $137.7M | $148.4M | $140.3M | $144.9M | $136.5M |
| Gross profit | $197.5M | $183.4M | $213.3M | $158.0M | $180.5M | $167.9M | $198.3M | $179.0M | $183.7M | $172.0M | $182.2M | $168.1M |
| Research & development | $15.5M | $16.3M | $14.9M | $13.9M | $14.1M | $12.9M | $13.2M | $13.6M | $14.1M | $13.6M | $14.0M | $12.5M |
| Sales, general & admin | $145.6M | $141.7M | $166.8M | $122.1M | $120.8M | $148.8M | $132.7M | $99.7M | $122.5M | $123.4M | $118.0M | $125.3M |
| Total operating expenses | $161.1M | $158.0M | $146.5M | $138.6M | $138.8M | $156.4M | $145.8M | $113.3M | $136.6M | $137.0M | $132.0M | $137.8M |
| Operating income | $36.4M | $25.4M | $66.9M | $19.4M | $41.7M | $11.5M | $52.5M | $65.7M | $47.1M | $35.0M | $50.2M | $30.3M |
| Interest expense | $7.9M | $7.1M | $7.4M | $7.6M | $7.8M | $8.3M | $8.9M | $9.3M | $9.6M | $9.6M | $9.5M | $10.0M |
| Income before taxes | $31.3M | $18.4M | $29.3M | $4.3M | $29.9M | $7.7M | $43.6M | $56.5M | $37.5M | $25.4M | $40.7M | $20.3M |
| Income taxes | $8.3M | $4.5M | $12.5M | $1.4M | $8.5M | $1.6M | $9.9M | $7.5M | $7.5M | $5.7M | $7.6M | $4.4M |
| Net income | $23.1M | $13.8M | $16.7M | $2.9M | $21.4M | $6.0M | $33.8M | $49.0M | $30.0M | $19.7M | $33.1M | $15.8M |
| EBITDA | $61.3M | $38.3M | $55.5M | $30.5M | $56.8M | $34.2M | $70.5M | $78.7M | $64.9M | $53.1M | $68.2M | $48.2M |
| EPS (diluted) | $1.38 | $0.89 | $1.43 | $1.08 | $1.15 | $0.95 | $1.34 | $1.05 | $0.98 | $0.79 | $1.06 | $0.90 |
| Gross margin | 57.5% | 57.9% | 57.1% | 46.7% | 52.6% | 52.6% | 57.3% | 56.5% | 55.3% | 55.1% | 55.7% | 55.2% |
| Operating margin | 10.6% | 8.0% | 17.9% | 5.7% | 12.2% | 3.6% | 15.2% | 20.7% | 14.2% | 11.2% | 15.3% | 9.9% |
| Net margin | 6.7% | 4.4% | 4.5% | 0.8% | 6.2% | 1.9% | 9.8% | 15.5% | 9.0% | 6.3% | 10.1% | 5.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CNMD's financial statements (latest annual report filed February 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CNMD financial results
In fiscal year 2025 (ended December 31, 2025), CONMED reported revenue of $1.4 billion, up 5.2% from the year before. It had net income of $47.1 million (down 64.5%), a net profit margin of 3.4%. Diluted earnings per share came to $4.61. Over five years revenue grew at an average rate of 9.8% a year.
See the CNMD stock overview for the latest quote and news, or the CNMD chart for price history and technical indicators.
CNMD income statement FAQ
What is CONMED's annual revenue?
CONMED reported total revenue of $1.4 billion for fiscal year 2025, which ended on December 31, 2025. That was up 5.2% from $1.3 billion the previous year.
Is CONMED profitable?
Yes. CONMED reported net income of $47.1 million in fiscal 2025, a net profit margin of 3.4%; its operating margin was 10.3%.
What is CONMED's gross margin?
CONMED's gross margin was 52.8% in fiscal 2025: for every $100 of revenue, CONMED kept $53 after the direct cost of its products and services.
How much does CONMED spend on research and development?
CONMED spent $55.9 million on research and development in fiscal 2025, 4.1% of revenue.
How fast is CONMED growing?
Revenue grew 9.8% a year on average over the last five fiscal years, from $862.5 million to $1.4 billion.
What are CONMED's earnings per share?
CONMED earned $4.61 per diluted share in fiscal 2025, compared with $4.16 a year earlier.
When will CONMED report its next earnings?
CONMED is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 after the market closes.
When does CONMED's fiscal year end?
CONMED's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 17, 2026.